[A21-32] Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2021
Project no.:
A21-32
Commission:
Commission awarded on 22.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Treatment of primary chronic immune thrombocytopenia in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-31 | Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V | Commission completed |